Melanoma is responsible for around 10,000 deaths annually in the US. While simple
excision can cure most melanomas, some progress into metastatic cancer, necessitating …

More patients diagnosed with stage I (local) melanoma die than any other metastatic stage,
because there exists no biomarker to reliably diagnose metastatic melanoma, preventing …

Metastatic melanoma is associated with a poor prognosis, but no method reliably predicts
which melanomas of a given stage will ultimately metastasize and which will not. While …

The therapeutic landscape of malignant melanoma has been radically reformed in recent
years, with novel treatments emerging in both the field of cancer immunotherapy and …

Uveal melanoma (UM) is the most frequent primary intraocular malignancy in adults,
characterized by melanin depositions in melanocytes located in the uveal tract in the eyes …

Melanoma diagnosis is clinically challenging: the accuracy of visual inspection by
dermatologists is highly variable and heavily weighted toward false positives. Even the …

Melanoma is one of the most dangerous forms of cancer. The five-year survival rate is 98% if
it is detected early. However, this rate plummets to 63% for regional disease and 17% when …

More people die from melanoma after a Stage I diagnosis than after a Stage IV diagnosis,
because the tools available to clinicians do not readily identify which early-stage cancers …

Targeted therapies and immunotherapies have transformed melanoma care, extending
median survival from∼ 9 to over 25 months, but nevertheless most patients still die of their …

9565 Background: Machine learning algorithms, and especially convolutional neural
networks, demonstrated modest accuracy on the prediction of melanoma metastasis, based …